(Q54110984)

English

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

0 references

1 reference

based on heuristic

inferred from title

author name string

Maraninchi D

1

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Vey N

2

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Viens P

3

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Stoppa AM

4

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Archimbaud E

5

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Attal M

6

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Baume D

7

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Bouabdallah R

8

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Demeoq F

9

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Fleury J

10

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Michallet M

11

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Olive D

12

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Reiffers J

13

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Sainty D

14

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Tabilio A

15

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Tiberghien P

16

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Brandely M

17

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Hercend T

18

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Blaise D

19

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

publication date

1 October 1998

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

31

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

3-4

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

343-349

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

https://api.crossref.org/works/10.3109%2F10428199809059227

21 January 2018

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

1 reference

https://api.crossref.org/works/10.3109%2F10428199809059227

21 January 2018

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

1 reference

https://api.crossref.org/works/10.3109%2F10428199809059227

21 January 2018

Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance

1 reference

https://api.crossref.org/works/10.3109%2F10428199809059227

21 January 2018

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.3109%2F10428199809059227

21 January 2018

The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission

1 reference

https://api.crossref.org/works/10.3109%2F10428199809059227

21 January 2018

Identifiers

10.3109/10428199809059227

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/9869198

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54110984&oldid=1240689757"